Histone Modifications is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Histone modifications are post-translational chemical alterations to histone proteins that regulate chromatin structure and gene expression without changing the DNA sequence. These epigenetic modifications - including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation - control the accessibility of DNA to transcriptional machinery and play fundamental roles in neuronal gene expression, synaptic plasticity, and memory formation. In neurodegenerative diseases, widespread dysregulation of histone modifications contributes to aberrant gene expression programs that promote neuroinflammation, synaptic loss, and neuronal death (Nativio et al., 2020). [1]
Histone deacetylase (HDAC inhibitors have emerged as promising therapeutic candidates for Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS, with several compounds advancing through preclinical and clinical development (Shukla & Singh, 2024). [2]
DNA in the nucleus is packaged around histone octamers to form nucleosomes, the fundamental units of chromatin: [3]
The "histone code hypothesis" proposes that specific combinations of histone modifications create a code read by effector proteins to regulate gene expression: [4]
The most studied histone modification in neurodegeneration: [5]
Mechanism: [6]
Effect: Neutralizes the positive charge on lysine, weakening histone-DNA interactions and opening chromatin for transcription. [7]
Key acetylation marks in the brain: [8]
| Mark | Location | Function | Change in AD | [9]
|------|----------|----------|-------------| [10]
| H3K9ac | Promoters | Gene activation | Globally decreased | [11]
| H3K14ac | Promoters | Gene activation | Decreased |
| H3K27ac | Enhancers, promoters | Active enhancer mark | Redistributed |
| H4K16ac | Gene bodies | Transcription elongation | Decreased |
| H4K12ac | Promoters | Memory-related gene expression | Decreased with aging |
Mechanism:
Key methylation marks:
Large-scale chromatin profiling studies have revealed widespread histone modification changes in AD brains:
HDAC inhibitors are the most advanced epigenetic therapeutic strategy for neurodegeneration:
| Compound | HDAC Selectivity | Status | Key Evidence |
|---|---|---|---|
| Vorinostat (SAHA) | Pan-HDAC (I, II) | FDA-approved (cancer) | Improves memory in AD mice; restores histone acetylation |
| Sodium valproate | Class I/IIa | FDA-approved (epilepsy) | Clinical trials in AD; mixed results |
| CI-994 (Tacedinaline) | Class I selective | Preclinical (AD) | Restores hippocampal memory gene expression |
| Tubastatin A | HDAC6 selective | Preclinical | Reduces tau phosphorylation and aggregation |
| RGFP966 | HDAC3 selective | Preclinical | Enhances memory consolidation |
| Compound 3 | HDAC11 selective | Preclinical (2025) | Brain-penetrant; colocalizes with amyloid plaques |
The study of Histone Modifications has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Graff J, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483(7388):222-226. DOI. 2012. ↩︎
Shukla S, Singh SS. Restoring the epigenome in Alzheimer''s Disease: advancing HDAC inhibitors as therapeutic agents. Drug Discov Today. 2024;29(8):104056. PMID: 38830501. 2024. ↩︎
Guan JS, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243):55-60. DOI. 2009. ↩︎
Peleg S, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 2010;328(5979):753-756. DOI. 2010. ↩︎
Konsoula Z, Bhatt AB. Epigenetics in neurodegenerative diseases. Biomolecules. 2024;16(1):103. DOI. 2024. ↩︎
Zheng Y, et al. The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther. 2022;7(1):217. DOI. 2022. ↩︎
Stilling RM, Fischer A. The role of histone acetylation in age-associated memory impairment and Alzheimer's Disease. Neurobiol Learn Mem. 2011;96(1):19-26. DOI. 2011. ↩︎
Fischer A, et al. Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447(7141):178-182. DOI. 2007. ↩︎
Chuang DM, et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11):591-601. DOI. 2009. ↩︎
Frost B, et al. Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014;17(3):357-366. DOI. 2014. ↩︎
Cook C, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet. 2014;23(1):104-116. DOI. 2014. ↩︎